Actinium Pharmaceuticals, Inc. Analyst Report: High Potential Emerging Biopharmaceutical Firm Nearing Phase 3 Trial Commencement for Innovative Cancer Treatments
NEW YORK, April 10, 2014 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), is an emerging biopharmaceutical company focused on the $54 billion market for cancer drugs. The Company's most advanced products are Actimab™-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab™-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications.
Actinium develops drugs for treatment of cancer intended to cure or significantly improve survival of the affected patients with lower side effect profiles. Products currently under development include monoclonal antibodies labeled with radioisotopes. The Company's APIT technology is based on attaching actinium 225 (Ac-225) or bismuth 213 (Bi-213) alpha emitting radioisotopes to monoclonal antibodies. Alpha emitting radioisotopes are unstable chemical elements that decay by releasing alpha particles. Alpha particles can kill any cell in whose immediate proximity they are released It is crucial for the success of these drug candidates to contain monoclonal antibodies that can successfully seek cancer cells and can kill them with the attached isotope while not harming nearby normal cells.
As with many cancer sub-categories there is a large available market with very few treatment alternatives particularly for ATNM's older target patients. ATNM's novel approach has no clear direct competition and has the potential to be disruptive in the market.
The Company has recently filed its FY2013 Form 10K annual financial report and related disclosures which provide an update on operating considerations and the latest financial information for investors.
An analyst report which details key attributes of the products, intellectual property, an overview of the company and analyst commentary can be viewed in its entirety by using the link below. There is no cost required to view this report:
copy and paste to browser may be required.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Michael Andereg, CFA. An outsourced research services provider represented by Michael Andereg, CFA, provided Small Cap Street, LLC this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Small Cap Street, LLC is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Michael Andereg, CFA.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at email@example.com. For any urgent concerns or inquiries, please contact us at firstname.lastname@example.org.
NO WARRANTY OR LIABILITY ASSUMED
ATNM has not compensated Small Cap Street, LLC or Michael Andereg, CFA for the creation or dissemination of this report. Small Cap Street, LLC is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. Small Cap Street, LLC does not hold any positions in ATNM. No liability is accepted by Small Cap Street, LLC whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Street, LLC expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Street, LLC does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
Michael Andereg, CFA, is the author of research report. Small Cap Street, LLC has compensated Michael Andereg, CFA two hundred dollars and fifty dollars for the right to disseminate this report. Information in this release is fact checked and produced on a best efforts basis by Michael Andereg, CFA.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Small Cap Street, LLC